Research summary

This page summarises known side effects of prescription human growth hormone (somatropin) in children and adults, drawing on sources such as Endocrine Society guidance, FDA labelling, and Cleveland Clinic patient materials.

Remy Research materials are for in-vitro laboratory research only, not human or veterinary use.

Summary written November 14, 2026, at first publication.

Update History ▾
November 14, 2026: Initial publication, citing the Endocrine Society adult growth hormone deficiency guideline, the NordiNet IOS and ANSWER registries, the GeNeSIS observational program and the European Medicines Agency assessment report for somatrogon.
Research-use-only framing applied throughout in line with Remy editorial standards.
Compliance note: this page is a research review, not a treatment guide. It does not provide human-use dosing, therapeutic recommendations, or any clinical-use instructions, and should be read in the same non-therapeutic frame required across Remy's research content.

Key Takeaways

This article examines what clinical evidence actually shows about the safety of full-length somatropin, who faces the greatest risk, and where scientific uncertainty still lingers.

This page summarises known side effects of prescription human growth hormone (somatropin) in children and adults, drawing on sources such as Endocrine Society guidance, FDA labelling, and Cleveland Clinic patient materials.

What Is Human Growth Hormone (HGH) and How Is It Used Clinically?

Human growth hormone is the full-length 191-amino-acid peptide secreted by the anterior pituitary gland. The pituitary gland releases HGH in pulses throughout the day, and this hormone regulates growth, body composition, and metabolism largely by stimulating production of insulin like growth factor 1 (IGF-1) in the liver and other tissues.

How HGH Differs From Fragments and GH‑Releasing Peptides

This article focuses exclusively on full-length human growth hormone (somatropin). Other research peptides related to the GH–IGF-1 axis have distinct mechanisms and safety questions that deserve separate treatment.

Mechanisms Behind HGH Side Effects

Most growth hormone side effects stem from HGH's systemic actions: stimulation of IGF-1 production, fluid and sodium retention, counter-regulatory effects on insulin signalling, and promotion of soft-tissue and connective-tissue growth. Understanding these mechanisms helps explain why the same molecule can be therapeutic at one dose and harmful at another.

Common Short‑Term Side Effects in Adults on Medically Supervised HGH

Clinical trials and registry data from the 2000s through 2020s show broadly consistent side-effect patterns in adults receiving growth hormone replacement for diagnosed deficiency. The Endocrine Society's clinical practice guidelines[1] provide a useful framework for what clinicians typically observe during dose titration.

Common Short‑Term Side Effects in Children Receiving HGH

In children treated for growth hormone deficiency or idiopathic short stature, safety data come from multi-year pediatric registries - such as NordiNet IOS and ANSWER, which together tracked approximately 37,700 children over 130,000 patient-years[2] - and from randomized controlled trial evidence in specific indications.

Metabolic Effects: Insulin Resistance, Glucose, and Lipids

HGH has complex effects on metabolism: it can improve body composition by reducing body fat and increasing lean mass, but it sometimes worsens insulin sensitivity, especially at higher doses or in predisposed individuals.

Cardiovascular Side Effects and Long‑Term Heart Risk

Cardiovascular outcomes remain one of the most studied but still debated areas of HGH safety, in both children and adults. The data span from structural cardiac measurements to population-level event rates.

Neurological and Ophthalmic Side Effects

Serious neurological adverse effects of HGH are rare but clinically important due to the potential for vision loss or debilitating headache, particularly in paediatric patients.

Musculoskeletal and Orthopedic Complications

Musculoskeletal side effects are among the most characteristic of HGH exposure, especially where growth velocity increases rapidly in paediatric patients or where supraphysiologic doses are used in adults.

Edema, Fluid Retention, and Weight Changes

Sodium and water retention is a core pharmacologic effect of growth hormone and a central driver of several early side effects. Fluid retention explains why many patients experience rapid, visible changes in the first weeks of therapy.

Endocrine Interactions: Thyroid and Other Hormones

Growth hormone interacts with multiple endocrine axes beyond insulin, most notably thyroid function and cortisol metabolism. These interactions explain why specialist endocrine supervision is a standard part of any HGH treatment protocol.

Neoplasm and Cancer Risk: What the Evidence Shows So Far

Because GH and IGF-1 are growth-promoting molecules, the question of whether HGH may contribute to the growth of cancerous tumors has attracted intense study in cohorts treated since the mid-1980s. The evidence is nuanced and still evolving.

HGH Side Effects in Children: Growth, Puberty, and Long‑Term Outcomes

For children with true growth hormone deficiency or specific syndromic causes of short stature, the benefits on adult height and quality of life are often substantial. Nonetheless, long-term safety is monitored closely across multiple domains.

HGH Side Effects in Adults: Men, Women, and Older Patients

Common search queries about "HGH side effects in men" or "HGH side effects in women" reflect the fact that while core risks are shared, some sex-specific and age-related nuances exist.

Sex‑Specific and Reproductive Considerations

GH interacts with sex steroids and may have indirect effects on fertility and reproductive physiology, primarily studied in the context of deficiency and assisted reproduction.

HGH Misuse in Bodybuilding, Sport, and Anti‑Aging Clinics

Many online questions about growth hormone side effects relate not to medically indicated treatment but to unapproved "performance" or "age-reversal" protocols, where doses are far higher and monitoring is typically absent.

Differences Between Daily and Long‑Acting Weekly HGH Formulations

Since approximately 2015, long-acting weekly somatropin formulations (e.g., somatrogon, somapacitan, lonapegsomatropin) have been developed and, in some cases, approved to reduce injection burden for patients.

Counterfeit, Contaminated, and Unregulated HGH Products

A significant, separate category of risk arises not from HGH biology itself but from the quality and authenticity of products obtained outside regulated medical channels.

Laboratory and Monitoring Strategies in Clinical HGH Therapy

Understanding how endocrinologists track safety during growth hormone replacement provides context for why non-medical use without monitoring is particularly risky - and why so many growth hormone side effects go undetected until they become severe in unsupervised settings.

Unanswered Questions and Long‑Term Uncertainty

Despite decades of research, key questions about very long-term safety - especially for those treated from early childhood into later adult life - remain incompletely answered.

Ethical and Regulatory Context of HGH Use

HGH occupies a complex ethical space: essential for some patients with genuine deficiency, yet widely misused for enhancement and performance in the broader culture.

How Remy Research Positions HGH‑Axis Peptides for Laboratory Use

While this article focuses on clinical and safety evidence, Remy Research operates strictly within the research-chemical domain, serving scientists rather than patients.

Practical Takeaways for Clinicians, Researchers, and Readers

This article has covered a broad terrain. Here are the main safety themes, distilled for different audiences.

Our Research Standards

This overview draws on clinical practice guidelines, long-term registry studies and regulator assessment reports for prescription somatropin, and keeps supervised medical use apart from non-medical use. Where long-term data are missing, we say so directly. No therapeutic, dosing or administration guidance is given. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews Remy's peptide research library, with a focus on analytical verification, clinical-trial interpretation, and compliance-safe scientific communication.

About the editorial team →

Frequently Asked Questions About Growth Hormone Side Effects

Does medically supervised HGH therapy stunt natural growth or make children stop growing earlier?

In children with growth hormone deficiency, appropriate treatment generally increases final adult height rather than reducing it, by restoring closer-to-normal growth patterns and promoting growth during the critical childhood and puberty years.

Epiphyseal (growth plate) fusion is driven mainly by sex steroids during puberty, not by GH alone. Registries have not shown consistent evidence that standard-dose GH causes abnormally early growth plate closure in children with genuine deficiency.

Excess dosing above guideline targets could theoretically accelerate bone maturation, which is why paediatric endocrinologists monitor bone age, growth velocity, and gestational age history throughout therapy to calibrate dose appropriately.

Can short‑term HGH use for bodybuilding cause permanent side effects?

Transient effects such as fluid retention, joint pain, and carpal tunnel syndrome often reverse after discontinuation, distinguishing them from structural changes that require prolonged exposure.

However, acromegaloid changes in bones and organs usually require years of excess exposure, while metabolic changes such as insulin resistance or new-onset diabetes may become permanent in susceptible individuals even after shorter misuse. Carpal tunnel syndrome is a rare side effect of HGH therapy but may persist if nerve damage has occurred.

Because illicit use typically occurs without monitoring, actual risk in any given person is unpredictable and may be amplified by concurrent substances such as anabolic steroids, insulin, or stimulants.

Are HGH side effects different in people with already low HGH levels compared with healthy users?

Many clinical trials involve truly GH-deficient patients, where replacement aims to restore physiologic levels. In such patients, treatment frequently improves symptoms, body composition, and some risk markers. Side effects still occur but are usually manageable and often outweighed by benefits when therapy is correctly dosed.

In non-deficient individuals, added HGH typically raises IGF-1 - the like growth factor 1 IGF that mediates most of GH's peripheral effects - above the physiological range, shifting the balance toward side effects and away from clinically meaningful benefit.

Is there any way to gain the "benefits" of HGH without injections or side effects?

No pill or over-the-counter supplement has been convincingly shown to replicate prescription-strength HGH effects on height or body composition in controlled trials. So-called "HGH boosters" and secretagogue supplements sold online often have unverified ingredients and can still carry safety and contamination risks without delivering meaningful benefits.

Lifestyle factors - adequate sleep, resistance exercise, managing visceral fat, avoiding smoking and heavy alcohol consumption - support the body's own GH–IGF-1 axis and overall metabolic health with far lower risk. These approaches broadly support energy, metabolism, and healthy age-related hormonal patterns.

How should researchers approach GH‑related experiments given the clinical side effect profile?

Laboratory scientists designing in-vitro or animal studies should consider clinically relevant concentration ranges, exposure durations, and endpoints that reflect known human risks - for example, insulin signalling, proliferative pathways, and cardiac hypertrophy markers.

Including appropriate controls (vehicle, IGF-1 only, growth hormone releasing hormone analogues) helps dissect pathway-specific effects highlighted in clinical oncology and cardiometabolic literature. Researchers should also consider dose-equivalent comparisons reflecting the range between physiologic replacement and supraphysiologic exposure.

Extrapolating from bench data back into unsupervised human use is inappropriate. Such research should instead inform regulated translational pipelines and risk–benefit assessments led by clinical investigators operating within institutional ethics frameworks.

Sources

  1. Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609. academic.oup.com ↩
  2. Sävendahl L, Polak M, Backeljauw P, et al. Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER. J Clin Endocrinol Metab. 2021;106(6):1728-1741. pubmed.ncbi.nlm.nih.gov ↩
  3. Child CJ, Zimmermann AG, Chrousos GP, et al. Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program. J Clin Endocrinol Metab. 2019;104(2):379-389. pmc.ncbi.nlm.nih.gov ↩
  4. European Medicines Agency, Committee for Medicinal Products for Human Use. Ngenla (somatrogon) assessment report, procedure EMEA/H/C/005633/0000, EMA/15620/2022. December 16, 2021. ema.europa.eu ↩

For catalog details, see the Genovare HGH 100IU AQ Pen and the Genovare HGH Fragment 176-191 25mg AQ Pen. For editorial standards, continue to the editorial policy.